Thermo Fisher Scientific expands Direct-to-Patient Clinical Trials service offerings

October 27, 2020  – Thermo Fisher Scientific announced it has expanded its Direct-to-Patient service offering that supports decentralized clinical trials to minimize clinical trial length and costs while maximizing patient enrollment and participation rates.

The offering now includes Clinical Site-to-Patient, Pharmacy-to-Patient and Depot-to-Patient services to enable clinical trial medication delivery directly to patients’ homes.

Thermo Fisher Scientific’s expanded Direct-to-Patient services build on its global Clinical Site-to-Patient program that launched earlier this year to ensure clinical trial patients have uninterrupted access to life-saving investigational drug shipments without having to visit a clinic.

Thermo Fisher Scientific says that the program can support any trial phase and a range of trial variables including Interactive Response Technology (IRT) systems, blinded/unblinded and home nursing providers. Clinical Site-to-Patient services are available in 47 countries and have supported more than 1,500 shipments to patients worldwide to help treat more than 25 different indications.

Direct-to-Patient also offers end-to-end cold chain management and traceability and centralized storage of clinical trial material, reducing waste and minimizing the storage space needed at clinical sites.

Learn More

safe online pharmacy for viagra cheap kamagra oral jelly online